NewsPUBMEDMar 28
This is an editorial article that introduces a special collection of scientific papers about gene therapy for rare diseases. Gene therapy is a treatment that fixes or replaces faulty genes that cause disease. The editorial discusses how gene therapy is becoming an important treatment option for rare diseases that affect small numbers of people.
WHY IT MATTERSThis editorial highlights the growing momentum in gene therapy development for rare diseases, which means more treatment options may become available for conditions that previously had few or no approved therapies.
ResearchPUBMEDMar 26
Researchers created a new method to build growth charts for children with rare genetic disorders. Instead of needing thousands of patients, this method uses a smaller group of patients and compares their growth to standard growth charts. They tested it on six rare genetic disorders and found it works well, which could help doctors track whether children with these conditions are growing normally.
WHY IT MATTERSParents and doctors caring for children with ANKRD11, ARID1B, ASXL3, DDX3X, KMT2A, or SATB2-related disorders can now use gene-specific growth charts to monitor their child's growth instead of comparing to general population standards that don't apply to their condition.
ResearchCLINICALTRIALSMar 26
Researchers completed a study testing whether an artificial intelligence tool can help regular doctors better diagnose skin conditions. The AI was designed to reduce mistakes and unnecessary specialist referrals by giving primary care doctors better information about skin problems like melanoma, psoriasis, and other conditions. With only 9 participants, this was a small early-stage study to see if the technology works.
WHY IT MATTERSIf this AI tool works well, patients with rare skin conditions like hidradenitis suppurativa could get faster, more accurate diagnoses from their regular doctor instead of waiting for specialist appointments.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new treatment for calciphylaxis, a serious condition where calcium builds up in blood vessels and skin tissue, causing painful sores. The treatment uses special cells from amniotic fluid (the fluid around a baby during pregnancy) to see if they can help heal the damage. This is an early-stage trial with a small group of 9 patients to check if the treatment is safe and works.
WHY IT MATTERSCalciphylaxis has very few treatment options and high mortality rates — this trial offers patients with chronic kidney disease a chance to access an experimental stem cell therapy that could reduce tissue damage and improve survival.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called furmonertinib in patients with advanced lung cancer that has specific genetic mutations. This is an early-stage study (Phase 1) with 160 patients to see if the drug is safe and how well it works. The drug targets uncommon mutations in EGFR and HER2 genes that some lung cancer patients have.
WHY IT MATTERSThis trial addresses treatment options for patients with advanced NSCLC carrying uncommon EGFR or HER2 mutations, which typically have fewer targeted therapy options than common mutations.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called zipalertinib to treat advanced lung cancer in patients who have a specific genetic mutation called EGFR exon 20 insertion. This mutation makes lung cancer harder to treat with standard medications. The study is looking for 220 patients to see if zipalertinib is safe and effective for this type of cancer.
WHY IT MATTERSThis trial targets EGFR exon 20 insertion mutations in advanced NSCLC, a genetic subtype that historically has limited treatment options and poor response to standard EGFR inhibitors.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for patients with a specific type of lung cancer (non-small-cell lung cancer with EGFR PACC mutations) who have never received treatment for advanced disease. This study will test whether a new drug called firmonertinib works better and is safer than two existing drugs (osimertinib or afatinib) that doctors currently use. About 480 patients will be enrolled worldwide.
WHY IT MATTERSThis trial is actively recruiting patients with EGFR PACC mutations—a rare subset of lung cancer—and offers access to firmonertinib, a potentially more effective treatment option compared to standard first-line therapies.
ResearchCLINICALTRIALSMar 26
Researchers at St. Jude Children's Research Hospital are recruiting 385 people—including patients, families, doctors, and scientists—to share their thoughts about ethical questions that come up when testing new treatments for rare brain and nerve diseases. The study wants to understand what different groups of people think is fair and right when designing these small, personalized treatment trials.
WHY IT MATTERSThis study directly shapes how future rare neurological disease trials will be designed and conducted, meaning your input as a patient or caregiver could influence the ethical standards that protect you in future treatment studies.